Navigation Links
Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
Date:4/16/2013

PRINCETON, N.J., April 16, 2013 /PRNewswire/ -- Omthera Pharmaceuticals, Inc., an emerging specialty pharmaceutical company focused on the development and commercialization of new therapies for abnormalities in blood lipids, referred to as dyslipidemia, today announced the closing of its previously-announced initial public offering of 8,000,000 shares of its common stock at $8.00 per share.  Omthera's common stock is listed on the NASDAQ Global Market under the trading symbol "OMTH". All shares of common stock were offered by Omthera Pharmaceuticals, Inc.

BofA Merrill Lynch, Barclays and Leerink Swann acted as joint book-running managers for the offering; Stifel and Piper Jaffray served as co-managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 11, 2013.  The offering was made only by means of a prospectus, copies of which may be obtained from: BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, or via email, at dg.prospectus_requests@baml.com, from Barclays, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by calling (888) 603-5847, or by emailing barclaysprospectus@broadridge.com, or from Leerink Swann, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by calling (800) 808-7525 ext. 4814.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such st
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
2. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
3. Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
4. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
5. Avion Pharmaceuticals, LLC., announces further expansion of their Womens Health Sales Team
6. Covis Pharmaceuticals, Inc Named US Distributor For Five Additional Products
7. Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
8. Harwood Feffer LLP Announces Investigation of Spectrum Pharmaceuticals, Inc.
9. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spectrum Pharmaceuticals, Inc.
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results
11. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Fourth Quarter and Year-End 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... THE WOODLANDS, Texas , Nov. 26, 2014 ... LXRX ) today announced the completion of previously ... of $280.0 million.  After fees and estimated offering ... million from the transactions.  The transactions consisted of: ... shares of common stock, pursuant to a registration ...
(Date:11/26/2014)... , Nov. 26, 2014 Scott Steiger lives ... of the world. As an engineer for the past 20 years, ... of the military service. He,s been to six of the seven ... Photo - http://photos.prnewswire.com/prnh/20141126/161076 Photo - http://photos.prnewswire.com/prnh/20141126/161077 ... travelers, he has a pretty good idea of what,s required. ...
(Date:11/26/2014)... 26, 2014  Aridis Pharmaceuticals, Inc., a biopharmaceutical ... for infectious diseases, announced today the addition of ... key opinion leader in the areas of pneumonia ... Founder and Chief Executive Officer, ... Opal,s extensive experience investigating bacterial toxins and key ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Steiger Has Created the First Pill Case Specifically Designed For Travel 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3
... Iclaprim also achieved high eradication rates for ... Staphylococcus aureus (MRSA), REINACH, Switzerland, Oct. ... combined results from two pivotal Phase III,clinical ... Antimicrobial Agents,and Chemotherapy (ICAAC)/Infectious Diseases Society of ...
... Paratek Pharmaceuticals, Inc. today,announced positive Phase 2 data ... aminomethylcycline (AMC). The Phase 2 study compared,safety and ... PTK 0796 to,Zyvox(R) in the treatment of patients ... trial met its primary safety and,tolerability endpoint, demonstrating ...
Cached Medicine Technology:Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 2Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 4Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 5Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 6Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 7Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4
(Date:11/28/2014)... (PRWEB) November 28, 2014 On Monday, ... and Sendik’s will present Feeding America Eastern Wisconsin with ... Food Market to donate a portion of proceeds to ... Sendik’s promotion, “7 Days, 7 Ways to Save” with ... Fyffes pineapples were two for $4 and Turbana bananas ...
(Date:11/28/2014)... Miami's Plastic Surgery of the Face recently ... Dr. Jeffrey Epstein is excited to offer patients ... platform, the site is uniquely designed for easing viewing ... 75% of all prospective rhinoplasty patients research upcoming procedures ... on with smartphones, tablets, and laptops, as well as ...
(Date:11/28/2014)... Written and narrated by award winning author Dr. ... “The Happiest Man In the World: Life Lessons From a ... why Project C.U.R.E. came to be. , Raised in the ... Reverend Richard W. Jackson, Dr. Jackson exceeded his goal of ... that he wasn’t happy. Prompted by this realization, James and ...
(Date:11/28/2014)... November 28, 2014 Not only is ... products free of petroleum, parabens and other cancer-causing agents, ... fund research, education and awareness programs that help in ... and owners have raised an incredible, record-breaking contribution of ... Cure, sales of the Sweet Red Rose Whip Moisturizer ...
(Date:11/28/2014)... Mabel’s Labels , the market ... an award-winning company established by four moms, today announced ... Tricia Mumby have been honored with a 2014 RBC ... PROFIT Award for Excellence in Entrepreneurship. , All 4 ... Mumby) accepted the award on behalf of Mabel’s Labels ...
Breaking Medicine News(10 mins):Health News:Turbana Partners With Sendik's Food Market to Donate $11,500 to Local Hunger-Relief Non-Profit 2Health News:Turbana Partners With Sendik's Food Market to Donate $11,500 to Local Hunger-Relief Non-Profit 3Health News:Top Rhinoplasty Surgeon Launches Innovative Website 2Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 3
... Status Quo of U.S. Health Care,System, According to Deloitte ... 30 More than 750,000,Americans left the country last ... grow to six million by 2010, potentially costing the,U.S. ... in operation,has also soared by 220 percent from just ...
... ABC, NBC ... and CBS, ... adventures of parenting, announced that "Viva la,Familia! de Todobebe" (Hooray for Families! ... night July 25th in Prime,Time delivering 3.3 million viewers 2+ and made ...
... JACKSONVILLE, Fla., July 30 TriServ Alliance recently,submitted ... to support delivery of,health care for the third ... TriServ will begin servicing the 2.9 million active,duty, ... of the,uniformed services, their families and beneficiaries on ...
... Expanded to Include Two ACRO Representatives, WASHINGTON, ... (ACRO) and the Metrics Champion Consortium,(MCC) are pleased ... to the MCC Board of Directors. In an ... the MCC, a multidisciplinary organization,whose mission is to ...
... as a legitimate means of encouraging organisational change ... adversely affect those involved. , Dr Jane ... examined the psychological impact on members of the ... 2004-2006. , She found strikers reported higher ...
... Nonprofit to List of Supported Philanthropies , ... ... www.CollaborateMD.com [CollaborateMD]], a leading provider of on-demand practice management ... for Humanity International], which builds and rehabilitates small houses with ...
Cached Medicine News:Health News:Explosive Growth in Medical Tourism and Rise of Retail Clinics Provide Huge Cost Savings for Patients 2Health News:Explosive Growth in Medical Tourism and Rise of Retail Clinics Provide Huge Cost Savings for Patients 3Health News:Explosive Growth in Medical Tourism and Rise of Retail Clinics Provide Huge Cost Savings for Patients 4Health News:Explosive Growth in Medical Tourism and Rise of Retail Clinics Provide Huge Cost Savings for Patients 5Health News:Todobebe's New Family TV Show Debuts as #1 Show in the U.S. Among All Adults 18 to 34 2Health News:MCC Names ACRO Leaders to Board of Directors 2Health News:Psychological downside to strike action 2Health News:CollaborateMD Becomes a Habitat for Humanity International HopeBuilder 2
This table has adjustable height, an integral leg, and blade post. Includes a standard 2" (5 cm) pad....
... is designed for use without ... allowing for full C-Arm access. ... stored onboard when more stability ... quickly slide into standard sockets ...
... The onboard rail clamps ... O.R. tables and stretchers. ... any need for lifting. ... a stable surface combined ...
... The powered torso and ... Orthopedic Trauma Table simultaneously lift ... independent lift mechanism raises and ... for precise positioning. A wide ...
Medicine Products: